Sign In
Buy EGRX
$0.460
+0 (+0%)
At Close: Jun 03, 2026
Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) - February 9, 2024 Deadline to Join - Contact Levi & Korsinsky
04:30pm, Thursday, 08'th Feb 2024
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi
EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit
04:15pm, Thursday, 08'th Feb 2024
LOS ANGELES , Feb. 8, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit again
Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming Deadline
03:20pm, Thursday, 08'th Feb 2024
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming February 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of invest
NEW YORK , Feb. 8, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsui
LOS ANGELES, CA / ACCESSWIRE / February 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX
03:20pm, Wednesday, 07'th Feb 2024
NEW YORK , Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investo
EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit
02:15pm, Tuesday, 06'th Feb 2024
LOS ANGELES , Feb. 6, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against
NEW YORK , Feb. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities
LOS ANGELES, CA / ACCESSWIRE / February 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("
-- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (“FDA”) for rescue treatment of postoperative nausea and vomiting (“PONV
Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
11:19am, Monday, 27'th Nov 2023
Eagle Pharmaceuticals (EGRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
11:17am, Friday, 10'th Nov 2023
The heavy selling pressure might have exhausted for Eagle Pharmaceuticals (EGRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre
Eagle Delays Third Quarter 2023 Results and Conference Call
07:30am, Thursday, 09'th Nov 2023
WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will be delaying the release of its third
Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023
08:30am, Wednesday, 08'th Nov 2023
WOODCLIFF LAKE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its third quarter 20
